Compare SVAQ & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SVAQ | VCRE |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.0M | 316.4M |
| IPO Year | 2025 | 2026 |
| Metric | SVAQ | VCRE |
|---|---|---|
| Price | $10.07 | $10.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 25.2K | 8.0K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.86 | $10.47 |
| 52 Week High | $10.16 | $13.15 |
| Indicator | SVAQ | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 62.80 | 43.48 |
| Support Level | $10.00 | $10.75 |
| Resistance Level | $10.12 | $13.00 |
| Average True Range (ATR) | 0.02 | 0.57 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 41.18 | 25.75 |
Silicon Valley Acquisition Corp is a blank check company.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.